PACT pharma press releases
Oct 02, 2019
PACT Pharma Appoints Tim Moore as President and Chief Technical Officer
The pace of innovation and development for CAR-T therapies over the past several years has increased dramatically. There are only a handful of people at the center of the action,” said Alex Franzusoff, CEO of PACT Pharma. “Tim, among this select group, has successfully led his team to bring these complex medicines to market, and his experience with CAR-T therapies at Kite will be invaluable as PACT seeks to establish new frontiers defining personalized cell therapies for patients with solid tumors.
Jul 21, 2019
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
PACT Pharma, a leader in the fields of cancer immunology and cell therapy in collaboration with a team at UCLA, presented new data demonstrating for the first time the ability to identify mutation targets unique to each person’s cancer and verify the cancer specificity of multiple cloned T cell receptors. Each patient’s cancer has a private signature of mutations, creating an opportunity to develop fully personalized immune therapies that have the potential to eradicate tumor cells.